Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study.

< BACK TO ARCHIVE


Papers: 25 Jul 2020 - 31 Jul 2020


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2020 Jul 26


Cephalalgia


http://www.ncbi.nlm.nih.gov/pubmed/32715736?dopt=Abstract

Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study.

Authors

Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study.
De Icco R, Fiamingo G, Greco R, Bottiroli S, Demartini C, Zanaboni A, Allena M, Guaschino E, Martinelli D, Putortì A, Grillo V, Sances G, Tassorelli C
Cephalalgia. 2020 Jul 26:333102420942230.
PMID: 32715736.

Abstract

Anti-calcitonin gene-related peptide antibodies proved effective in the preventive treatment of chronic migraine. In this open label study, we aim to assess the effects of erenumab administration on neurophysiological and biomolecular profiles in a representative cohort of chronic migraine patients.
Read This Paper